ArticleFrontiers in public health2026
Quality and reliability of semaglutide-related health information on Chinese short-video platforms: a cross-sectional study of Bilibili and TikTok.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Semaglutide, a glucagon-like peptide-1 receptor agonist originally developed for glycemic control, has recently gained widespread attention for its weight-loss effects. With the rapid rise of short-video platforms, these media have become important channels for disseminating health information. However, the quality, reliability, and underlying determinants of semaglutide-related content on such platforms have not been systematically characterized. Methods: A cross-sectional content analysis was conducted on semaglutide-related videos from Bilibili and TikTok. Videos were collected on February 4, 2026. Two independent reviewers evaluated the quality of each video using the Global Quality Scale (GQS), modified DISCERN (mDISCERN), and Journal of the American Medical Association (JAMA) benchmark criteria. Multivariable regression analyses were performed to identify factors associated with information quality. Results: A total of 225 videos were included (107 from Bilibili and 118 from TikTok). Most videos focused on weight loss (82.2%), while only 2.7% primarily discussed hypoglycemic effects. The overall median scores were 4.0 (3.0-4.0) for GQS, 4.0 (3.0-5.0) for mDISCERN, and 2.0 (1.0-3.0) for JAMA. TikTok videos had significantly higher JAMA scores than Bilibili videos (median 3 vs. 1, Conclusion: Semaglutide-related videos on Chinese short-video platforms demonstrated relatively high subjective quality and usability (mDISCERN and GQS), but markedly lower adherence to formal transparency benchmarks (JAMA), with substantial variability driven primarily by uploader professional background. Content produced by medical professionals tends to provide more reliable information, while engagement metrics do not consistently reflect information quality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.